共 12 条
[1]
Gurbel PA(2016)Platelet-mediated thrombosis: from bench to bedside Circ. Res. 118 1380-1391
[2]
Jeong YH(2005)Platelet reactivity in patients and recurrent events post-stenting: results of the PREPARE POST-STENTING Study J. Am. Coll. Cardiol. 46 1820-1826
[3]
Navarese EP(2016)Vascular risk levels affect the predictive value of platelet reactivity for the occurrence of MACE in patients on clopidogrel. Systematic review and meta-analysis of individual patient data Thromb. Haemost. 115 844-855
[4]
Tantry US(2008)Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: a multicenter randomized prospective study J. Am. Coll. Cardiol. 51 1404-1411
[5]
Gurbel PA(2010)Long-term clinical outcome based on aspirin and clopidogrel responsiveness status after elective percutaneous coronary intervention: a 3T/2R (tailoring treatment with tirofiban in patients showing resistance to aspirin and/or resistance to clopidogrel) trial substudy J. Am. Coll. Cardiol. 56 1447-1455
[6]
Reny JL(2011)Standard- versus high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial JAMA 305 1097-1105
[7]
Bonello L(2012)Bedside monitoring to adjust antiplatelet therapy for coronary stenting N. Engl. J. Med. 367 2100-2109
[8]
Campo G(2013)Prasugrel 5 mg in the very elderly attenuates platelet inhibition but maintains noninferiority to prasugrel 10 mg in nonelderly patients: the GENERATIONS trial, a pharmacodynamic and pharmacokinetic study in stable coronary artery disease patients J. Am. Coll. Cardiol. 62 577-583
[9]
Price MJ(2012)Platelet function during extended prasugrel and clopidogrel therapy for patients with ACS treated without revascularization: the TRILOGY ACS platelet function substudy JAMA 308 1785-1794
[10]
Collet JP(undefined)undefined undefined undefined undefined-undefined